Literature DB >> 2886598

Effect of age on gastrointestinal and hepatic first-pass effects of levodopa in rats.

K Iwamoto, J Watanabe, M Yamada, F Atsumi, T Matsushita.   

Abstract

Presystemic elimination of levodopa (20 mg kg-1) has been studied in 5- to 104-week-old male Wistar rats. The gastrointestinal and hepatic contribution to the overall first-pass effect was estimated separately after the drug had been administered intravenously, orally and intraportally. The contribution of the gut to the overall first-pass effect of this drug was greater than that of the liver in any age-group of the rats. Both the overall and intestinal first-pass effects of levodopa were greatest in 11-week-old rats and relatively small in both young (between weeks 5 and 7) and aged (between weeks 52 and 104) rats. In contrast, the hepatic first-pass effect did not show any significant age-dependent change. Age-related change in the jejunal blood flow could not explain the unique age-dependence in the intestinal first-pass metabolism of levodopa. However, the present age-dependence in the oral systemic availability of this drug between adult (11 weeks) and aged (52 to 104 weeks) rats was found to be similar to the tendency that has been reported between normal adult subjects and aged patients with Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2886598     DOI: 10.1111/j.2042-7158.1987.tb03413.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  5 in total

1.  Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease.

Authors:  M Contin; R Riva; P Martinelli; F Albani; A Baruzzi
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  A pharmacokinetic model to predict the PK interaction of L-dopa and benserazide in rats.

Authors:  S Grange; N H Holford; T W Guentert
Journal:  Pharm Res       Date:  2001-08       Impact factor: 4.200

Review 3.  Individual variation in first-pass metabolism.

Authors:  Y K Tam
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

Review 4.  Contributions of Gut Bacteria and Diet to Drug Pharmacokinetics in the Treatment of Parkinson's Disease.

Authors:  Sebastiaan P van Kessel; Sahar El Aidy
Journal:  Front Neurol       Date:  2019-10-15       Impact factor: 4.003

5.  Gut bacterial deamination of residual levodopa medication for Parkinson's disease.

Authors:  Sebastiaan P van Kessel; Hiltje R de Jong; Simon L Winkel; Sander S van Leeuwen; Sieger A Nelemans; Hjalmar Permentier; Ali Keshavarzian; Sahar El Aidy
Journal:  BMC Biol       Date:  2020-10-20       Impact factor: 7.431

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.